ERBB2 and hypoparathyroidism-retardation-dysmorphism syndrome: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD).